Home > Articles > Published articles > Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis : > Comments
 
 
Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis : An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes - Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Dossenbach, Martin (Eli Lilly and Company) ; Berggren, Lovisa (Lilly Deutschland GmbH) ; Ljungberg, Anders (Eli Lilly and Company) ; Zachariae, Claus (University of Copenhagen) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>

Similar records

UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with